Actualités

Novanta's second quarter was marked by broad-based organic growth across all business units and a favorable response from the market. Management attributed the strong results to both an acceleration in new product revenue—up more than 50% year-over-year—and operational improvements, including factory consolidations. CEO Matthijs Glastra highlighted that all business units grew organically and pointed to increased customer demand in precision robotics, AI-driven manufacturing, and minimally invas

Organic growth hit a three-year high as AI and robotics demand accelerated.

What Novanta’s latest guidance and Q2 results mean for the stock Novanta (NOVT) put fresh numbers on the table on 5 August 2026, pairing new third quarter and full year revenue guidance with second quarter results and the recently closed Riverpoint Medical acquisition. The company now guides third quarter 2026 GAAP revenue to US$300 million to US$304 million, with the range reflecting an expected contribution from Riverpoint Medical and an assumption of steady foreign exchange rates. For full...

Novanta Inc (NOVT) delivered robust Q2 2026 results with 9% organic growth, record cash flow, and raised full-year guidance following the Riverpoint Medical acquisition.

Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa

Novanta (NOVT) delivered earnings and revenue surprises of +7.23% and +1.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Universal Display (OLED) delivered earnings and revenue surprises of +1.92% and -3.93%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novanta was recently upgraded to a Zacks Rank #2 (Buy), reflecting increased analyst optimism tied to an upward revision in earnings estimates. This earnings-driven upgrade highlights how changing expectations about Novanta's profit outlook can influence investor attention and perceived business strength over time. Next, we'll examine how the upgraded earnings outlook and analyst ranking could reshape Novanta's existing investment narrative and risk profile. Invest in the nuclear...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Novanta (NASDAQ:NOVT) and its peers.

Novanta’s first quarter saw a strong positive market reaction, reflecting confidence in management’s execution and commercial momentum. The company credited broad-based demand and robust bookings, particularly in the Robotics & Automation and Advanced Surgery businesses, as central to its performance. CEO Matthijs Glastra highlighted that every segment achieved double-digit bookings growth, with new product revenue rising sharply. Management specifically pointed to ongoing strength in medical co

Shareholders of Novanta Inc. ( NASDAQ:NOVT ) will be pleased this week, given that the stock price is up 14% to US$156...

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) will be announcing earnings results this Monday after market close. Here’s what to expect.

This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings.

Novanta Inc (NOVT) reports impressive revenue and bookings growth, driven by AI and robotics, while navigating cost pressures and geopolitical uncertainties.

Novanta (NOVT) just posted first quarter results that beat earnings and revenue expectations, with sales of US$257.71 million and forward guidance above analyst estimates, marking a shift after earlier quarters of missed forecasts. See our latest analysis for Novanta. The strong first quarter beat and improved guidance appear to be feeding into momentum, with the share price up 11.8% over the past month and a year to date share price return of 26%. This is despite the 3 year total shareholder...

Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive

Moby summary of Novanta Inc.'s Q1 2026 earnings call

Novanta (NOVT) delivered earnings and revenue surprises of +3.85% and +1.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Ouster (OUST) delivered earnings and revenue surprises of +19.36% and +6.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?